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Down-Regulation of the Oncogene Cyclin D1
Increases Migratory Capacity in Breast Cancer and
Is Linked to Unfavorable Prognostic Features
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The oncogene cyclin D1 is highly expressed in many
breast cancers and, despite its proliferation-activating
properties, it has been linked to a less malignant phe-
notype. To clarify this observation, we focused on two
key components of malignant behavior, migration and
proliferation, and observed that quiescent G0/G1 cells
display an increased migratory capacity compared to
cycling cells. We also found that the down-regulation of
cyclin D1 in actively cycling cells significantly increased
migrationwhile also decreasing proliferation.When an-
alyzing a large set of premenopausal breast cancers, we
observed an inverse proliferation-independent link be-
tween cyclin D1 and tumor size and recurrence, sug-
gesting that this protein might abrogate infiltrative ma-
lignant behavior in vivo. Finally, gene expression
analysis after cyclin D1 down-regulation by siRNA con-
firmed changes in processes associated with migration
and enrichment of our gene set in a metastatic poor
prognosis signature. This novel function of cyclin D1
illustrates the interplay between tumor proliferation
and migration and may explain the attenuation of
malignant behavior in breast cancers with high cy-
clin D1 levels. (Am J Pathol 2010, 177:2886–2897; DOI:
10.2353/ajpath.2010.100303)
Breast cancer represents the most frequently diagnosed
disease in women in the Western world with 1 million new
patients annually. Even though the five-year survival rates
are as high as 86%, mortalities still total approximately
410,000 each year.1 Distant metastases from the primary
tumor represent the main cause of these deaths,2 and as
such, identification of new prognostic markers and tar-
gets for novel treatments of patients at risk of developing
metastases is of paramount importance.
The process of metastasis represents a complex se-
ries of events, comprehensively covering many functional
capabilities of a cell. These include tumor cell migration/
proliferation and invasion into the tissues surrounding the
primary tumor location, their subsequent intravasation
into the blood or lymph vessels, extravasation back through
vasculature to distal organs, and finally colonization/pro-
liferation and angiogenesis of a new location to produce
a second tumor body.3
Research in this area has focused on elucidation of the
factors involved in metastasis initiation, and a plethora of
candidates have been described in this setting; VEGF is
reported to promote metastatic colonization and desmo-
plasia in breast tumors,4 gene expression analysis indi-
cates an overexpression of DNA repair genes is associ-
ated with tumor metastasis,5 and recently, the role of the
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cell cycle regulatory protein cyclin D1 in the progression
of metastatic events has also been addressed.6–8
Cyclin D1 along with its binding partners CDK4/6 par-
tially mediate G1 to S-phase transition in the cell cycle.
9
Overexpression of the protein has been reported in 25 to
60% of invasive breast carcinomas and amplification of
its corresponding gene CCND1 occurs in 10 to 30% of
cases.10–12 Previous studies by our group and others
have implicated cyclin D1 with less aggressive tumor
characteristics such as lower histological grade and re-
tained pRb function.11,13 This suggests that activation of
the oncogene cyclin D1 in breast cancer could be linked
to less aggressive tumor properties and reduced meta-
static potential–a novel hypothesis given the protein’s
well-described proliferation enhancing properties. To
clarify this apparently conflicting relationship between
cyclin D1 and aggressiveness, we have focused on two
key components in breast cancer malignancies, migra-
tion and proliferation. In this study, we demonstrate how
cyclin D1 influences these properties using cell line mod-
els, in vivo studies of large collections of primary breast




The human breast cancer cell line MDA-MB-231 and the
melanoma cell line MDA-MB-43514 (ATCC, Int., Manas-
sas, VA) were maintained in RPMI 1640 medium supple-
mented with 10% fetal calf serum (FCS), sodium pyruvate
(1 mmol/L) and 1xPEST (streptomycin 90 g/ml, penicillin
90 IU/ml). Cells were maintained in a humidified atmo-
sphere of 5% CO2/95% air at 37°C.
Synchronization and Flow Cytometry
For synchronization, 1  106 cells were seeded in 28.3-
cm2 culture dishes and quiesced in 4 ml serum-free
medium (SFM) for 24 hours. The SFM was then replaced
with medium containing 10% FCS (SM) and the cells
were grown for 4, 8, 12, 16, and 20 hours, respectively
before harvest. For asynchronous experiments, 5  105
cells were seeded in 28.3-cm2 culture dishes and cul-
tured for 24 hours in SM before harvest. For flow cyto-
metric analyzes we refer to Berglund et al.15
Assessment of Ki-67 Expression
1  105 cells were seeded in 12.6-cm2 culture dishes
and synchronized as described above. At each time
point, cells were washed once with PBS and fixed for 30
minutes in PBS containing 4% paraformaldehyde. After
fixation, cells were washed once and subsequently per-
meabilized in PBS containing 2% NP-40. After washing,
cells were allowed to air-dry before incubation for 1 hour
primary antibody against Ki-67 (M7240, DAKO, Glostrup,
Denmark, diluted 1:25 in PBS). Cells were washed three
times in PBS before incubation (1 hour) with a FITC-
conjugated secondary antibody (F0313, DAKO, 1:50 in
PBS). After a final wash step, cells were stained with DAPI
(46-diamidino-2-phenylindole) and mounted with a glass
coverslip. Images of the Ki-67-FITC/DAPI–stained cells
were taken using a fluorescence microscope, and the
analysis of Ki-67 fluorescence intensities was carried out
with the Image-Pro Plus software (Media Cybernetics,
L.P., MD). DAPI staining allowed cell nuclei to be defined
and the intensity of green light/Ki-67 expression quanti-
fied. From the continuous light intensities measured, a
cut-off for Ki-67-positivity was arbitrarily chosen based on
the visually detectable limit.
Treatment with U0126
The MEK1/2 inhibitor U0126 (Sigma-Aldrich, St. Louis,
MO), dissolved in dimethyl sulfoxide (DMSO), was used
at a concentration of 20 mol/L with an equal volume of
DMSO used as control and both were added to SM as
required. For assessment of ERK1/2 phosphorylation and
migratory capacity, cells were pretreated with U0126 or
DMSO for 4 hours before the migration assays. In addi-
tion, the medium in the chambers and wells was supple-
mented with U0126 or DMSO.
siRNA and Vector Transfections
5 105 cells were seeded in a 28.3-cm2 culture dish with
PEST-free SM for 24 hours. The media was subsequently
removed and PEST-free SFM added along with 1 ml
siRNA solution (OptiMEM, Gibco, Lipofectamine 2000,
Invitrogen Life Technologies, Carlsbad, CA) giving a final
concentration of 40 nmol/L oligonucleotides. Five hours
after transfection, SFM was replaced with SM and cells
were allowed to grow for 20 hours before harvesting for
migration assay, flow cytometry or Western blot. ON-
TARGETplus SMARTpool siRNA reagents targeting cyclin
D1 (excluding duplex J-003210-15 due to nonspecific
effects, Dharmacon RNA Technologies, Lafayette, CO),
CDK4 and CDK6 were included as standard experimen-
tal protocol. A nontargeting pool was used as negative
control. For vector experiments, 3 g of GFP-tagged
vector with an insert of the ORF of cyclin D1, or GFP only
(control) was used (OriGene Technologies Inc., Rock-
ville, MD). Cyclin D1 transfection efficiency was 45% as
determined by flow cytometry analyses of the GFP-
tagged cyclin D1 construct, and total cell numbers were
quantified by migration assay.
Western Blotting
Western blot was performed as described previously,15
and the following antibodies were used: -cyclin D1 (1:
500, DCS-6, DAKO, Glostrup, Denmark), -cyclin E (1:
500, HE12, Santa Cruz Biotechnology, Santa Cruz, CA),
-cyclin A2 (1:500, Santa Cruz), -p21 (1:500, SX118,
DAKO), -phospho-pRb Ser807/811 (1:500, Cell Signal-
ing Technology, Inc., Beverly, MA), -pRb (1:500, IF8,
Santa Cruz), -phospho-p44/42 MAP Kinase Thr202/
Tyr204 (1:500, Cell Signaling Technology, Inc.), and
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-p44/42 MAP Kinase (1:500, Cell Signaling Technology,
Inc.) -CDK4 (1:500, DCS-35, Chemicon, Rockford, IL),
-CDK6 (1:1000, DCS83, Cell Signaling Technology,
Inc.). Actin (1:1000 I-19, Santa Cruz) was included as
loading control. Densitometric analysis of Western blot of
phospho bands was performed and corrected with the




Cell migration was routinely carried out in 8-m-pore
polycarbonate membrane Transwell chambers with a di-
ameter of 6.5 mm (Corning, Inc. Corning, NY). The mem-
branes were incubated in 150 l serum-free RPMI 1640
for an initial equilibrium period of 1 hour. Cells were
resuspended in serum-free medium (1  106 cells/ml),
and 100,000 cells were added to each migration cham-
ber. The chambers were placed into wells containing 600
l 10% FCS medium, and cells were allowed to migrate
for 3 hours or overnight, after siRNA or vector transfec-
tions, respectively. Cells remaining in the chamber were
removed with a cotton swab, and the migrated cells
situated on the lower side of membranes were fixed for 15
minutes in PBS containing 4% paraformaldehyde. Mem-
branes were cut and mounted on glass slides for DAPI
staining and counted using a fluorescent microscope
(cells in three 10 magnification fields representing the
composition of the membrane were counted). Assays
were repeated at least three times with at least three
migration chambers for every treatment. Each migration
assay was related to the mean number of migrated con-
trol siRNA treated cells in that particular experiment to
avoid interexperimental variation. This is termed “relative
unit” in the figures. Each dot in the figure represents one
migration chamber.
Time Lapse Microscopy
For time lapse experiments cells were plated at a conflu-
ency of 2  104 cells/cm2 in a 24-well plate after trans-
fection with siRNA, before being placed in an enclosed
full environmental chamber surrounding a Zeiss Axiovert
200M microscope. Sample, gases, chamber, and objec-
tive lens were environmentally maintained and monitored.
Visualization was undertaken with Metamorph (Molecular
Devices, Downingtown, PA) and a Roper Coolsnap HQ
camera, with three fields of view imaged per well. Images
were taken every 5 minutes for 4 hours, and once cap-
tured data were exported to Metamorph for particle track-
ing analysis. Particle data were subsequently imported to
Image J and analyzed the with the Ibidi chemotaxis
plug-in.
Cell Sorting for Cell Cycle Analysis
MDA-MB-231 cells were resuspended at 1 106 cells/ml
in 500 l 10 g/ml Hoechst 33342 (Sigma) and incubated
for 45 minutes at 37°C. 7AAD (10 l/1  106 cells) (BD
Biosciences) was subsequently added to cells and incu-
bated for 15 minutes at room temperature to allow exclu-
sion of dead cells from sorting. After incubation, cells
were sorted at 16PSI by FACS using a BX Influx (BD
Biosciences) operated using Spigot software. FlowJo
version 7.6.1 analysis software (Treestar, Inc., Ashland,
OR) was used to set gates for sorting of cells into three
populations G0/G1, S, and G2/M. Cells were collected in
PBS and transwell migration assays performed as previ-
ously described with the exception that 50,000 cells were
seeded in upper chambers of membranes and allowed to
migrate for 5 hours.
Microarray Analysis
MDA-MB-231 cells were transfected with control, cyclin
D1, and CDK4/6 siRNA as described previously, har-
vested 12 hours posttransfection and resuspended in
RNeasy Lysis Buffer (QIAGEN Sciences, Germantown,
MD) before RNA isolation and microarray analysis by
AROS Applied Biotechnology A/S (Aarhus, Denmark).
Experiments were made in triplicates. Briefly, RNA ex-
traction was performed using TRIzol reagent (Invitrogen,
Carlsbad, CA) with subsequent quantification on Nano-
drop (ND-1000) Spectrophotometer at an optical density
of A260 nm. RNA was then labeled using the TotalPrep
RNA Labeling Kit (Ambion, Austin, TX) before hybridiza-
tion to the whole genome Illumina Human WG-6 v3.0
Expression gene chip (Illumina, San Diego, CA). Raw
data were examined in BeadStudio (Illumina, Inc.), with
subsequent quantile normalization and identification of
differentially expressed genes performed by significance
analysis of microarrays (SAM)17 in R18, using the lumi19
and siggenes BioConductor packages,20 respectively.
Data were then exported to the GoMiner high-throughput
web-interface to determine significant gene ontology pro-
cesses and to gene-set enrichment analysis software
(GSEA, Broad Institute MIT) for comparison to previously
published data sets and functional processes.
Analysis of Primary Tumors
The immunohistochemical analysis was conducted with a
formalin-fixed paraffin-embedded tumor material consist-
ing of 500 primary invasive stage II breast cancers from
premenopausal patients. These patients were enrolled in
a previously described randomized clinical trial of adju-
vant tamoxifen treatment.21 The tumors were assembled
in tissue microarrays (TMAs) followed by the procedure
described in Berglund et al.15 Cyclin D1 intensity had
been assessed previously as absent  0, low  1, inter-
mediate  2, and strong  3,22 as had Ki-67, which was
analyzed as fraction of positive nuclei where 0 0 to 1%,
1  1 to 10%, 2  11 to 25%, 3  26 to 50%, and 4  51
to 100%.23 For tumor growth pattern analysis, the char-
acteristics of the tumors had been previously evaluated
on whole tumor sections. Growth patterns were classified
into four groups, defined by the mode of infiltration, from
the most infiltrative cases with a “sieving” and diffuse
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tumor border (“exclusively infiltrative”) to a more pushing,
clearly defined tumor margin (“exclusively pushing”).
Other than these two extreme groups, two intermediary
groups were also defined as either demonstrating “predom-
inantly infiltrative” or “predominantly pushing” growth. For
the present analysis, the “exclusively infiltrative” group of
tumors was analyzed against the remainders of tumors,
included in the group here termed “pushing feature.” For
more details on the assessment of growth pattern and rep-
resentative images, we refer to Berglund et al.24 Evaluation
of phosphorylated pRb was performed by using an -phos-
pho-pRb antibody targeting phosphorylation sites Ser807/
811 (1:200, cat. no #9308, Cell Signaling Technology, Inc.,
Beverly, MA).
Statistical Methods
To examine the statistical significance of the differences
seen in the Boyden migration assays and in the distribu-
tion of cell cycle phases, a two-tailed Student’s t-test was
used, assuming unequal variance. Unless stated other-
wise, the SEM is shown. Further on, Spearman’s rank-
order correlation coefficient () was used to test the sta-
tistical significance of the association between cyclin D1
nuclear intensity and various categorical variables. For
estimation of recurrence-free survival, the Kaplan–Meier
method, log-rank test and Cox regression analyses were
used. Analyses were carried out using the SPSS software
(version 15.0, SPSS, Chicago, IL) and a P value less than
0.05 was considered significant.
Results
Cell Cycle Specific Variations in the Protein
Expression and Migratory Capacity of
MDA-MB-231 Cells
To determine the baseline migratory behavior of breast
cancer cells in relation to cell cycle phase distribution, we
synchronized MDA-MB-231 cells by serum starvation for
24 hours followed by serum stimulation and assessed
proliferation, expression of cell cycle related proteins and
migratory behavior at consecutive time-points. Cells en-
tered a resting G0-like phase after of serum starvation,
and proceed through G0/G1 and S- phases after 12 and
16 hours of serum stimulation, respectively (Figure 1A).
Expression of the cell cycle regulatory proteins cyclin D1,
cyclin E, and cyclin A2 peaked in consecutive order over
a 24-hour period with concomitant increasing phosphor-
ylation of pRb. The CDK inhibitor p21 exhibited an early
transient peak similar to that of phospho-ERK1/2 with
expression of both proteins declining as cells entered
S-phase (Figure 1B). The fraction of cells positive for the
proliferation marker Ki-67 decreased substantially after
24 hours of serum starvation but increased after 12 hours
of serum stimulation indicating entrance into active cell
cycle (Figure 1C).
We next used a Boyden chamber assay for examina-
tion of cell migratory capacity. Cells serum stimulated for
up to 8 hours exhibited an average of 2.9  0.15-fold
increase in migration relative to actively cycling control
Figure 1. Effect of cell phase on MDA-MD-231 cell cycle protein expression and migration. Cells were quiescent for 24 hours before serum stimulation and
monitored at the indicated times for changes in cell phase distribution, cell-cycle related protein expression, and migration. Control is nonquiescent, actively
cycling cells. Blots are representative, histograms and migration plots are averaged from at least three independent experiments. A: Cell phase analysis by flow
cytometry. B: Cyclin D1, cyclin E, cyclin A2, p21, pRb, phospho-pRb, ERK1/2, and phospho-ERK1/2 expression by Western blot. C: Ki-67 expression analyzed
by immunocytochemistry. D: Cell migration analyzed by Boyden chamber assay. Twenty-four hour SM vs. 24 hours SFM  8 hours SM, P  0.001 two-tailed
Student’s t-test. SM, serum medium; SFM, serum-free medium.
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cells. After 12 and 16 hours, however, this had fallen to
1.2  0.11 and 0.80  0.11-fold of control, respectively
(Figure 1D). These results suggest that resting G0/early
G1 cells have greater migratory abilities compared with
both late G1/S-phase and G2/M cells as well as unsyn-
chronized, actively cycling cells.
MDA-MB-231 Cell Cycle Progression and
Migration Are Partially Modulated through
ERK1/2 Phosphorylation
As ERK1/2 phosphorylation has been established as par-
ticipating in cell migratory and cycling activities,25–27 we
decided to assess the significance of the observed phos-
phorylation of the protein after 4 and 8 hours of serum
stimulation. For this, the specific inhibitor of the ERK1/2
phosphorylation protein MEK, U0126, was used with sub-
sequent examination of MDA-MB-231 cell phase distribu-
tion and migration. Initial investigations revealed a de-
tectable band of ERK1/2 phosphorylation 15 minutes
after serum stimulation that increased and maintained
intensity up to a 3 hours time point (Figure 2A). This band
was absent after the inclusion of U0126 in the serum-
containing media (Figure 2B). In addition, treatment with
the inhibitor reduced the cells migratory ability by 40%
(Figure 2C) and prevented cell cycle progression to S-
phase on serum stimulation (Figure 2D). Cyclin D1 pro-
tein levels were not affected by MEK inhibition (data not
shown). Taken together, these results suggest that the
migratory capacity of G0/early G1 cells is strongly influ-
enced by, but not solely dependent on, ERK1/2 activity.
Silencing of the Cyclin D1 Gene Increases
MDA-MB-231 and MDA-MB-435 Cell Migration
in a CDK4/6-Independent Manner
After the observed link between proliferation and migration
in serum starved and partially synchronized cells we exam-
ined the role of the main G1-cyclin, cyclin D1, in a migratory
and proliferative capacity with actively cycling MDA-MB-
231 and -435 cell lines. Cyclin D1 protein was efficiently
down-regulated using siRNA with subsequent diminished
pRb phosphorylation and proliferation in MDA-MB-231 but
not MDA-MB-435 cells (Figure 3, A, B and E, F). In parallel
with the decrease in cyclin D1 expression, a substantial
increase in ERK1/2 phosphorylation in MDA-MB-231 but not
MDA-MB-435 cells was found. Interestingly, both cells lines
displayed significantly increased migration after cyclin D1
silencing (1.7  0.19 and 1.8  0.14-fold, respectively)
relative to control transfected cells in Boyden chamber
assay (Figure 3, C and G) and by time-lapse micros-
copy in MDA-MB-231 cells (Figure 3D). A comparable
result was found when using an alternative siRNA se-
quence targeting cyclin D1 in MDA-MB-231 cells by
Boyden chamber assay (see Supplemental Figure 1, A
and B at http://ajp.amjpathol.org).
Simultaneous silencing of the cyclin D1 associated
kinases CDK4 and CDK6 in actively cycling MDA-MB-
231 cells resulted in a similar reduction in pRb phosphor-
ylation and proliferation with concurrent increase in
ERK1/2 phosphorylation (Figure 3, H and I). Notably, cell
migration was unaffected relative to control after CDK4/6
silencing (Figure 3J). These results indicate that in-
creased migration in both MDA-MB-231 and MDA-MB-
435 cells after cyclin D1 silencing is ERK1/2 and CDK4/6
independent.
To further demonstrate that the migration difference
observed after cyclin D1 silencing was not due to unspe-
cific siRNA effects, we reintroduced cyclin D1 to cyclin
D1 siRNA-silenced MDA-MB-231 cells. As illustrated in
Figure 4, A and B, overexpression of the protein in cyclin
D1 silenced cells decreased migration significantly com-
pared to a control vector, again confirming the impor-
tance of cyclin D1 in breast cancer cell migratory behav-
ior. To investigate whether the cyclin D1–mediated
increase in migration was specific for a cell cycle phase
we sorted siRNA transfected cells using the DNA dye
Figure 2. Effect of MEK1/2 inhibitor U0126 on MDA-MB-231 cell phase distribution and migration. Cells were quiescent for 24 hours before serum stimulation
in the absence or presence of 20 mol/L U0126 and monitored at the indicated times for changes in phospho-ERK1/2 expression, cell phase distribution, and
migration. Control is DMSO-treated cells. Blots are representative, and histograms and migration plots are averaged from at least three independent experiments.
A: Short-term phospho-ERK1/2 expression by Western blot. Densitometric analysis of phospho-ERK1/2 bands was corrected with the values of respective total
ERK1/2 bands and actin. B: Phospho-ERK1/2 expression after inhibitor treatment by Western blot. C: Cell migration analyzed by Boyden chamber assay. ***P 
0.001, two-tailed Student’s t-test. D: Cell phase distribution analyzed by flow cytometry. SM, serum medium; SFM, serum-free medium.
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Hoechst 33342. As illustrated in Figure 5A, the most
pronounced increase in migration (relative to control)
after cyclin D1 silencing occurred in the S- and G2/M
phases of the cell cycle, with limited effects in G0/G1
phase. An increase was also noted in migratory capac-
ity of control siRNA treated G0/G1 cells compared to S
and G2/M cells, confirming our initial observations in
Figure 1A.
Differential nuclear and cytoplasmic expression of cy-
clin D1 was observed in a large proportion of actively
cycling MDA-MB-231 cells (Figure 5B) revealing cyclin
D1 expression in multiple cell cycle phases.
Low Levels of Cyclin D1 Are Associated with an
Exclusively Infiltrative Tumor Growth Pattern and
Decreased Recurrence-Free Survival
Experimental findings were validated through examina-
tion of cyclin D1 protein expression in a primary breast
cancer material consisting of 500 tumors from premeno-
pausal patients. We focused on ER-positive tumors to
obtain a more homogenous group of breast cancer with
intact pRb machinery. As anticipated, strong cyclin D1
intensity correlated with both pRb phosphorylation and
high Ki-67 expression (Figure 6A), but not with tumor
grade or node status (Table 1). Notably, cyclin D1 inten-
sity was inversely correlated to tumor size (Table 1 and
Figure 6B) but no significant link was found between
Figure 3. Effect of cell cycle–related siRNA
treatment on MDA-MB-231, -435 cell-cycle, and
migratory properties. Unquiescent MDA-MB-231
cells were monitored 20 hours posttransfection
with the indicated siRNA (cyclin D1 or CDK 4/6)
for changes in cell cycle–related protein expres-
sion, cell phase distribution, and migration by
Boyden chamber assay and time-lapse micros-
copy. Blots are representative, and histograms
and migration plots are averaged from at least
three independent experiments. MDA-MB-231
cells: A: Western blot; B: cell phase distribution.
G0/G1 control versus cyclin D1 knockdown, P
0.001, two-tailed Student’s t-test. C: Cell migra-
tion by Boyden chamber assay. **P  0.003,
two-tailed Student’s t-test. D: Cell migration by
time-lapse microscopy, **P  0.006, two-tailed
Student’s t-test. MDA-MB-435 cells: E: Western
blot; F: cell phase distribution. G0/G1 control
versus cyclin D1 knockdown, P  0.056, two-
tailed Student’s t-test. G: Cell migration. ***P 
0.001, two-tailed Student’s t-test. MDA-MB-231
cells: H: Western blot; I: cell phase distribution.
G0/G1 control versus CDK4/6 knockdown, P 
0.001, two-tailed Student’s t-test. J: Cell migra-
tion. Control siRNA versus CDK4/6 siRNA, P 
0.30, two-tailed Student’s t-test. CDK, cyclin-de-
pendent kinase.
Figure 4. Reintroduction of cyclin D1 into cyclin D1–silenced MDA-MB-231
cells. A: Western blot of MDA-MB-231 cells. First lane shows untreated cells
as positive control for endogenous cyclin D1 (short arrow). Long arrow
indicates reintroduced GFP-tagged cyclin D1. B: Cell migration. **P  0.002,
two-tailed Student’s t-test.
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proliferation and tumor size (Table 1, summarized in Fig-
ure 6A).
Tumor growth pattern in relation to cyclin D1 expres-
sion was studied by defining tumors with an exclusively
infiltrative growth pattern (86% of total ER tumors) and
those with “pushing features” (14% of total ER tumors).
There was a significant overrepresentation of exclusively
infiltrative behaviors in cyclin D1 low and Ki-67 low tu-
mors (Figure 6C) and contrastingly, pushing behaviors
were linked to high cyclin D1 expression.
A further overrepresentation of absent or low cyclin D1
expression was observed in the highly infiltrative sub-
group of lobular breast cancer (see Supplemental Table
1 at http://ajp.amjpathol.org). Our findings of a negative
link between cyclin D1 and tumor size as well as infiltra-
tive behaviors in cyclin D1 low tumors supports the ex-
perimental findings that cyclin D1 down-regulation is
linked to increased tumor migratory properties.
We next examined the relationship between cyclin D1,
tumor size, and Ki-67 in relation to recurrence-free sur-
vival (RFS) in the untreated ER cohort. Interestingly,
cyclin D1 was positively and Ki-67 negatively associated
with RFS in a multivariate analysis independent of tumor
grade and lymph node status (Table 2), despite a posi-
tive link between cyclin D1 and proliferation (Table 1). We
next combined cyclin D1 and Ki-67 expression, con-
structing four subgroups: cyD1low/Ki-67low, cyD1low/Ki-
67high, cyD1high/Ki-67low, and cyD1high/Ki-67high. The
best and worst clinical outcomes were represented by
the cyD1high/Ki-67low and cyD1low/Ki-67high, respectively
(Figure 6D, left panel). Similar results were found when
tamoxifen-treated patients were included in the analysis
(Figure 6D, right panel). These results indicate that ab-
sent or low levels of cyclin D1 are associated with malig-
nant properties irrespective of proliferative status, further
validating our experimental findings.
Silencing of the Cyclin D1 and CDK4/6 Genes in
MDA-MB-231 Cells Impacts on Migration-Related
Cellular Processes
We next examined the response to cyclin D1 and CDK
4/6 silencing using a gene expression microarray ap-
proach, identifying a number of significantly altered
transcripts (see Supplemental Tables 2–5 at http://ajp.
amjpathol.org) and used the GoMiner program28 to
interpret the cell processes affected. As expected, nu-
merous proliferation-associated processes were altered
Figure 5. The effect of cyclin D1 silencing on
migration capacity of cells in different cell cycle
phases. A: MDA-MB-231 cells were sorted ac-
cording to cell cycle phase after siRNA treatment
and migration was assessed. Unsorted cells: con-
trol versus cyclin D1 siRNA, *P  0.018; S-phase:
control versus cyclin D1 siRNA, **P  0.001;
G2/M-phase: control versus cyclin D1 siRNA,
*P  0.04. G0/G1 phase versus S-phase, control
siRNA, **P  0.004. Two-tailed Student’s t-test.
B: Expression of cyclin D1 in actively cycling
MDA-MB-231 cells viewed by immunohisto-
chemistry at 40 magnification.
Figure 6. Correlation of cyclin D1 and Ki-67 expression to tumor size and
growth pattern in vivo. Five hundred tumors from ER premenopausal
breast cancer patients were evaluated for cyclin D1, Ki-67, and phos-pRb
protein expression. A: Schematic representation of the relationship between
cyclin D1, Ki-67, phospho-pRb, and tumor size. B: Relationship between
tumor size and cyclin D1 (Spearman’s rho  0.123, P  0.03). C: Distri-
bution of Ki-67 and cyclin D1 in tumors subgrouped based on exclusively
infiltrative versus pushing features. Highly proliferative tumors were signifi-
cantly overrepresented among tumors with pushing features (P  0.001, 2
test) as was strong cyclin D1 intensity (P  0.006, 2 test). D: Kaplan–Meier
curves illustrating the prognostic information of combining cyclin D1 and
Ki-67 expression in untreated patients (log rank test, P  0.011) and in
untreated and tamoxifen patients combined (log rank test, P  0.004).
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and notably, a number of processes traditionally associ-
ated with migration (including spindle, cytoskeleton and
microtubule changes) were increased in cyclin D1
siRNA, relative to CDK4/6 siRNA-treated cells, when both
were compared to control (Figure 7A).
Through direct comparison of the cyclin D1 and
CDK4/6 silenced gene lists we identified a set of gene
products that were only changed by cyclin D1 and not
CDK4/6 silencing (see Supplemental Table 6 at http://ajp.
amjpathol.org), potentially harboring candidate genes
mediating the cyclin D1 linked migration effect.
Finally, we compared our differentially expressed cy-
clin D1 silenced genes (relative to control silenced) to
published gene sets and known functional gene sets
using gene-set enrichment analysis (GSEA) software. Of
472 sets of genes whose products are involved in ‘met-
abolic and signaling pathways’ and 50 previously pub-
lished sets containing genes coregulated in response to
‘genetic and chemical perturbations,’29 two of the most
significant negatively enriched gene sets corresponded
to the ‘Vernell pRb cluster 1 study’30 (cluster 1 genes are
down-regulated by pRb) and the ‘G1 to S cell cycle
reactome’ (Figure 7B). As cyclin D1 is central in both
processes these results indicate the validity of using the
GSEA software to compare our gene set to published
data. Notably, our gene set was also negatively enriched
in genes (eg, FBXO5, MAD2L1, EZH2) correlated to poor
prognosis in breast cancer patients in the previously
published van’t Veer et al study (Figure 7C).31 These
results further implicate loss of cyclin D1 in breast cancer
cell migration and malignant tumor properties.
Discussion
Tumor cell migratory and proliferative processes are cen-
tral to the initiation and progression of tumor metastatic
events, and previous reports have proposed a contrast-
ing relationship between proliferative and infiltrative be-
haviors in cancer.15,32,33 Although it is not generally ap-
plicable to all malignancies, this may reflect relevant
biological characteristics of certain tumors and be of
potential clinical significance. Hence, we have delineated
how tumor cells combine proliferation with the process of
migration in both in vitro and in vivo settings.
Our initial investigations demonstrated that when qui-
escent and subsequently serum-stimulated MDA-MB-
231 breast cancer cells progress through cell cycle, they
have a peak migratory capacity during G0/G1 phases,
which declines as they progress into S-phase. Serum
stimulation of quiescent cells most likely evokes a multi-
tude of signaling events, making it challenging to derive
Table 1. Cyclin D1 Expression and Clinicopathological Parameters in ER Premenopausal Breast Cancer Patients
Variable Grade Node status Tumor size Ki67* Statistics
Cyclin D1† 0.059 0.038 0.123 0.263 rho‡
0.303 0.504 0.03 0.001 P value
310 312 311 272 N
Grade§ 0.056 0.151 0.450 rho
— 0.317 0.007 0.001 P value
319 318 277 N
Node status¶ 0.367 0.046 rho
— 0.001 0.439 P value
323 280 N
Tumor size|| 0.044 rho
— 0.469 P value
279 N
*Nuclear fraction (0–1%, 2–10%, 11–25%, 26–50%, 51–100%).
†Nuclear intensity (absent, low, intermediate, strong).
‡Spearman’s rho.
§Nottingham histological grade.
¶Lymph node metastasis: negative versus positive.
||Size in mm.
Table 2. Hazard Ratios for Recurrence-Free Survival in ER Patients in the Untreated Control Cohort Calculated with Cox
Uni- and Multivariate Analyses (N  173)
Univariate Multivariate
Variable HR 95% CI P value HR 95% CI P value
Cyclin D1* 0.818 0.625–1.070 0.143 0.711 0.5270.959 0.026
Grade† 1.905 1.354–2.680 0.001 1.449 0.931–2.256 0.101
Node status‡ 1.411 0.832–2.393 0.202 1.670 0.927–3.009 0.088
Tumor size§ 1.107 0.884–1.452 0.461 1.014 0.681–1.511 0.944
Ki67¶ 1.442 1.151–1.808 0.001 1.431 1.102–1.859 0.007
*Nuclear intensity (absent, low, intermediate, strong).
†Nottingham histological grade.
‡Lymph node metastasis: negative versus positive.
§Size in mm.
¶Nuclear fraction (0–1%, 2–10%, 11–25%, 26–50%, 51–100%).
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simple causal connections between proliferative and mi-
gratory responses. Despite this, the overall impression
from the experiments clearly suggests that these activi-
ties are to some extent coordinated. The decreased mi-
gratory potential concomitant with S-phase entrance is
most likely influenced by increased cell cycle activity. In
addition, the starved G0-population displayed a signifi-
cantly increased migratory capacity compared to asyn-
chronously growing populations containing few resting
G0 cells. This suggests that cells in G0 have a higher
migratory potential compared to actively cycling cells
and are more prone to migrate toward chemo-attractant
gradients. Moreover, actively cycling cells that continu-
ously cycle between a modified G1-phase and M-phase,
might have difficulties in combining a high level of prolif-
eration with efficient migration. This interpretation is sup-
ported by our previous work where cyclin E overexpres-
sion resulted in an increased S-phase population as well
as decreased cell motility and invasiveness.15
As the mitogen-activated protein (MAP)-kinase path-
way has been shown to regulate many cellular pro-
cesses, including proliferation and migration,26,27 we as-
sessed the role of one of its members, ERK1/2, in
influencing these properties of MDA-MB-231 cells. Our
findings indicate that its activity is not only necessary for
cell cycle progression but is also instrumental in migra-
tion. Moreover, silencing of cyclin D1 and CDK4/6 in
these cells elevated ERK1/2 phosphorylation, indicating
a novel mechanism whereby cyclin D1-CDK4/6 com-
plexes are able to regulate ERK1/2 activity. Initially, the
increased migratory capacity of cyclin D1 siRNA-si-
lenced cells appeared to be related to this elevation in
ERK1/2 activity, however two results challenged this hy-
pothesis. Silencing of CDK4/6 resulted in an elevated
ERK1/2 activity without affecting migration and cyclin D1
knock-down in MDA-MB-435 cells increased the migra-
tory capacity without affecting ERK1/2 activity. This im-
plies an ERK1/2-independent regulation of migration by
cyclin D1.
These observations were further reflected in cyclin D1–
silenced MDA-MB-231 and MDA-MB-435 cells, where de-
spite differences in the size of the G0/G1 populations and
phopsho-ERK1/2 expression between these cell types, mi-
gratory capacity was equivalently increased. Moreover,
even though silencing of the cyclin D1 binding partners
CDK4/6 increased the G0/G1 population, it did not enhance
the migratory capacity of the MDA-MB-231 cells. This sug-
gests cyclin D1 is able to modulate tumor cell migration by
mechanisms that are both CDK independent and unrelated
to the role of cyclin D1 in regulating proliferation. This as-
sessment is supported by previous reports showing that
cyclin D1 exerts CDK independent functions through bind-
ing and regulation of several transcription factors such as
the estrogen and androgen receptors, DMP1, STAT3, SP1,
and C/EBP.34,35 In addition, several cyclin D1-bound
genes have recently been identified in developing mouse
retinas and gene expression profiles of wild-type and cyclin
D1 knock-out mouse retinas suggesting that cyclin D1 can
both activate and down-regulate gene transcription, inde-
pendently of CDKs.36
The finding that high cyclin D1 levels would confer a
less migratory phenotype is somewhat contradicted by
the rapid up-regulation of cyclin D1 during the synchro-
nized cell phase experiments, where the migratory ca-
pacity peaks. Our data from flow cytometry sorted siRNA-
treated cells in different cell cycle phases nevertheless
suggests that with regard to migratory potential, it is
mainly S and G2/M cells that are affected by cyclin D1
silencing (Figure 5A). In contrast, synchronized cells hav-
ing high migratory capacity with concurrent high cyclin
D1 levels were predominantly in G0/G1 phase. This tends
toward a hypothesis that high cyclin D1 can be tolerated
in G0/G1 migratory cells, whereas S and G2/M cells have
a migratory advantage with reduced cyclin D1. Moreover
it suggests that cyclin D1 has distinct functions in differ-
ent cell cycle phases. This may also account for the
modest, yet significant, increase in migration of cyclin D1
silenced actively cycling cells consisting of a mixed pop-
ulation of cell cycle phases.
Previous studies have attempted to address the role of
cyclin D1 in breast cancer cell migration and Pestell et al
demonstrated cyclin D1/ mouse embryo fibroblasts
(MEFs) and mouse mammary epithelial cells (MECs) cells
have a reduced capacity to migrate.7,37 Ectopic cyclin
D1 expression in these cells resulted in an increased
movement velocity and this effect was dependent on the
ability of cyclin D1 to interact with CDK4 and p27. In our
model, the increased migration induced by silencing of
cyclin D1 occurred in the absence of p27 and could not
be mimicked by CDK knock-down. This implies that the
link between cyclin D1 and migration reported here is not
necessarily comparable with earlier reports. Future stud-
ies will address whether silencing of cyclin D1 in varying
Figure 7. Effect of cell-cycle related siRNA treatment on MDA-MB-231 cell
processes and gene set enrichment. Gene expression data were submitted to
GO miner and GSEA programs for analysis of gene ontology terms and data
set enrichment, respectively. A: GoMiner processes traditionally associated
with migration (spindle, cytoskeleton, and microtubule) were more fre-
quently changed in cyclin D1 siRNA-treated cells over CDK4/6 siRNA treat-
ment, when both were compared to control transfected cells. P  0.001 for
all processes. B: Comparison of genes changed after cyclin D1 siRNA treat-
ment of cells to published data sets and functional pathways (P  0.001). C:
Comparison to published poor-outcome gene expression set (P  0.04). ES,
enrichment score; NES, normalized enrichment score; FDR, false discovery
rate-adjusted q value.
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subtypes of breast cancer cells increases their migratory
capacity, however it is more likely that a genetic back-
ground of abnormalities influences how cyclin D1 affects
cell migration machinery.
To validate our experimental findings we analyzed cy-
clin D1 in a large cohort of ER premenopausal breast
cancer patients. We focused on ER breast tumors, as
ER tumors are often cyclin D1 negative, pRb-inacti-
vated, and highly proliferative, thus representing a sep-
arate entity of breast cancer.38,39 Translating our exper-
imental results to the in vivo situation would imply that
increased cyclin D1 levels should hamper infiltrative be-
havior, leading to overall reduced tumor aggressiveness.
As expected increased cyclin D1 expression correlated
to higher proliferation, however cyclin D1 was inversely
correlated with tumor size, which in turn, was not linked to
proliferation. Tumor size is a complex parameter that
reflects many clinical aspects, including both tumor cell
proliferation and infiltrative properties. As the size of a
tumor is defined as the largest diameter including tumor
cells marked and measured on a hematoxylin-eosin
stained slide, a tumor comprising highly invasive but
slowly proliferating cells may generally be of larger size
when compared to one which is highly proliferative and
less infiltrative. In this regard, our observation that tumors
expressing low levels of cyclin D1 were, in general, of
larger size, is in line with our in vitro findings.
We have previously analyzed the relationship between
cyclin E and tumor growth pattern and found cyclin E
high tumors to present with a less infiltrative, pushing
growth pattern.15,24 Despite the limitation of a small num-
ber of low infiltrative ER tumors in this cohort, a signif-
icant association was found between high levels of pro-
liferation and the presence of a pushing growth pattern,
and tumors with the highest cyclin D1 expression were
overrepresented among tumors with pushing features
relative to the exclusively infiltrative cases. Together with
the observation of an inverse association between cyclin
D1 and tumor size, this could indicate that increased
cyclin D1 expression impedes infiltrative behavior in vivo.
In the multivariate Cox analysis of untreated ER pa-
tients, cyclin D1 was an independent prognostic factor,
inversely linked to recurrence-free survival (Table 2).
Moreover, adding Ki-67 to our analysis successfully de-
fined subgroups of patients with significantly different
outcome and implied that cyclin D1 is linked to favorable
tumor properties that affect disease outcome indepen-
dently of both grade and node status.
It is pertinent to mention that our choice of cell lines
(MDA-MB-231, -435) does not directly match the proper-
ties exhibited by tumors in our cohort, and are ER-, PR-,40
and E-cadherin–41,42 negative. However, these cell lines
were chosen for their highly migratory and invasive qual-
ities.43 They are also vimentin-positive43 and represent
mesenchymal-like cells in the epithelial-mesenchymal
transition (EMT) system. The exact link between prolifer-
ation and migration in relation to EMT needs to be further
clarified in future studies, because EMT is relevant re-
garding both malignant and migratory properties in
breast cancer.44,45
Finally, to identify gene candidates that may be in-
creasing migration in response to decreased cyclin D1
expression we performed a gene expression microarray
experiment. Transcripts associated with cyclin D1 as well
as CDK4/6 silencing were identified separately, and there
was an overrepresentation of changes in processes as-
sociated with migration in the cyclin D1 siRNA–treated
cells compared to CDK4/6 siRNA–treated cells (Figure
7A). These results further support the observation from
Boyden chamber and time lapse experiments that cyclin
D1 has the capacity to influence breast cancer cell mi-
gration. As we only observed migratory differences in
cyclin D1 and not CDK4/6-silenced cells, we compared
the microarray results for the two treatments to identify
proteins potentially mediating this effect, while excluding
pure cell cycle–dependent changes. Transcripts up- or
down-regulated in the cyclin D1 siRNA treated cells, but
unaffected or moderately changed by the CDK4/6 siRNA
(see Supplemental Table 6 at http://ajp.amjpathol.org) in-
clude YAP1,46 CNN2,47 PTP4A1,48 ID1,49 IRS2,50 and
MAPK651 which have been linked to migration related
processes and are potentially important mediators in pro-
liferation and migration responses in tumors. However,
these candidate genes require significant experimental
analysis before any roles in proliferation and migration
with regard to cyclin D1 can be validated. Transcripts
associated with cyclin D1 silencing showed negative en-
richment of genes proposed by van’t Veer et al to predict
poor prognosis and a short interval to distant metasta-
sis31 in premenopausal breast cancer, again linking cy-
clin D1 with a migratory phenotype in patient samples.
Our results indicate several key processes in migration
may be influenced by the cyclin D1–specific effect (mi-
crotubule linked processes, actin binding, cytoskeleton,
focal adhesion), and it is likely that the mechanism by
which cyclin D1 executes functions is highly complex and
not mediated by a single pathway or gene product.
In summary, our findings establish a clear function for
cyclin D1 in tumor cell migration as well as proliferation
and further support an important role for the protein in
defining malignant behaviors in premenopausal breast
cancer.
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